Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från BioStock via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
2020-09-04 08:55:44
Yesterday, CombiGene announced the signing of a production agreement with the Spanish gene therapy manufacturer Viralgen for the production of the drug candidate CG01. The choice of partner is based on the fact that Viralgen can manufacture the candidate on a large scale, which means both cost savings and faster development of CG01, a gene therapy developed for the treatment of patients with drug-resistant focal epilepsy.
Read the full article about CombiGene at biostock.se:
https://www.biostock.se/en/combigene-gears-up-in-epilepsy-project/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/